{"entity":{"id":"nct07622017","kind":"trial","name":"KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer","aka":["K-BOOST"],"tldr":"A phase 2 trial of capecitabine, cAPOX (capecitabine, oxaliplatin) and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Gustave Roussy, Cancer Campus, Grand Paris, not yet recruiting.","summary":"KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer is a phase 2, interventional study registered as NCT07622017 by Gustave Roussy, Cancer Campus, Grand Paris, with a registry enrolment figure of 24 participants, started 2026-07 and due to reach its primary completion in 2029-01. Interventions recorded: KRC-01 (KORTUC); Radiotherapy; Capecitabine; CAPOX; FOLFOX; Optionnal TME. Conditions listed: Rectal Cancer. Primary outcome: Clinical Complete Response (cCR) Rate at Week 24. Colorectal eligibility wording from the registry: \"Histopathologically confirmed locally advanced rectal adenocarcinoma, stage III (high risk)\". Sites: France. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07622017","url":"https://clinicaltrials.gov/study/NCT07622017"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","imrt-igrt","platinum"],"targets":[],"drugs":["capecitabine","capox","folfox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07622017","phase":"2","setting":"Phase II Clinical Trial of KORTUC (KRC-01) Combined With Radiotherapy for Locally Advanced Rectal Cancer: Towards a New Organ Preservation Approach","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","enrolled":24,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07622017/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}